Cancer Research Annual Meeting 2010 EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, X.
Right arrow Articles by Bergan, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, X.
Right arrow Articles by Bergan, R. C.
Related Collections
Right arrow Preclinical Intervention
Right arrow Preclinical Intervention: In Vitro: Drugs, Mechanisms
[Cancer Research 65, 3470-3478, April 15, 2005]
© 2005 American Association for Cancer Research

Epidemiology and Prevention

Genistein Inhibits p38 Map Kinase Activation, Matrix Metalloproteinase Type 2, and Cell Invasion in Human Prostate Epithelial Cells

Xiaoke Huang, Shan Chen, Li Xu, Yueqin Liu, Dilip K. Deb, Leonidas C. Platanias and Raymond C. Bergan

Division of Hematology/Oncology, Department of Medicine, Northwestern University Medical School and the Robert H. Lurie Cancer Center of Northwestern University, Chicago, Illinois

Requests for reprints: Raymond C. Bergan, Division of Hematology/Oncology, Northwestern University, McGaw 2301, 240 East Huron Street, Chicago, IL 60611-3008. Phone: 312-908-5284; Fax: 312-503-4744; E-mail: r-bergan{at}northwestern.edu.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Epidemiologic studies associate consumption of genistein, in the form of dietary soy, with lower rates of metastatic prostate cancer. We have previously shown that genistein inhibits prostate cancer cell detachment in vitro, that it is well tolerated in an older cohort of men with prostate cancer, and that it alters cell signaling in that same cohort. We have also shown that p38 mitogen-activated protein kinase (MAPK) is necessary for transforming growth factor ß (TGF-ß)–mediated increases in prostate cancer adhesion. Although cell invasion is closely linked to metastatic behavior, little is known about how this process is regulated in prostate cancer or what effect, if any, genistein has on associated processes. We now show that genistein inhibits matrix metalloproteinase type 2 (MMP-2) activity in six of seven prostate cell lines tested, blocks MMP-2 induction by TGF-ß, and inhibits cell invasion. Efficacy was seen at low nanomolar concentrations, corresponding to blood concentrations of free genistein attained after dietary consumption. Inhibition of p38 MAPK by either SB203580 or dominant-negative construct blocked induction of MMP-2 and cell invasion by TGF-ß. Genistein exerted similar effects and was found to block activation of p38 MAPK by TGF-ß. This study shows that p38 MAPK is necessary for TGF-ß–mediated induction of MMP-2 and cell invasion in prostate cancer and that genistein blocks activation of p38 MAPK, thereby inhibiting processes closely linked to metastasis, and does so at concentrations associated with dietary consumption. Any potential causal link to epidemiologic findings will require further investigation.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Consumption of dietary genistein (4',5,7-trihydroxyisoflavone) in the form of soy has been associated with lower rates of metastatic prostate cancer as well as mortality from prostate cancer (1, 2). Genistein exhibits activity in several preclinical model systems that relate to cancer prevention and is considered a cancer chemopreventive agent (for reviews, see refs. 3, 4). Genistein is being tested in clinical trials by us (5) and by others (6–8). Although a variety of disparate mechanisms have been ascribed to genistein (3, 4), mechanistic studies typically use concentrations that greatly exceed those seen in humans who subsist on soy, no single mechanism has been closely linked with chemoprevention, and no clinical efficacy has been shown. Because chemopreventive agents must be administered over long periods without toxicity, yet must be given at doses associated with effective concentrations, mechanistic studies need to take these parameters into consideration (9). Studies of genistein that take into consideration mechanisms that operate at physiologically relevant concentrations are needed and can shed light on a widely consumed agent that may have cancer chemopreventive activity.

The pharmacokinetic parameters of oral genistein have been extensively evaluated in animals (10), in human dietary studies (11), and in prospective human studies, by us (5) and others (6–8). As a result of first-pass metabolism in the liver, only 1% to 10% of total circulating genistein is free (i.e., nonconjugated). Even after dosing with amounts of genistein that represent at least an 8-fold excess over that associated with daily dietary consumption (i.e., 8 mg/kg/d), peak concentrations of free genistein in the blood are only in the low to mid nanomolar range (5–8). Average steady-state blood levels in Japanese men, who subsist on a soy-based diet, were 0.28 µmol/L for total genistein, whereas concentrations of free genistein were much lower and ranged between 3 and 15 nmol/L (11). In the same study, concentrations in red meat–consuming Westerners were shown to be 2 logs below these levels. Taken together, these studies show that differential consumption of genistein is associated with differential concentrations in the blood. This is a necessary prerequisite if in fact genistein were exerting cancer chemopreventive effects as a function of differential dietary consumption. These data also suggest that relevant concentrations of free genistein are in the low nanomolar range.

Epidemiologic studies suggest that age-adjusted rates of clinical (i.e., metastatic) prostate cancer are ~10-fold lower among soy-consuming Southeast Asians, as compared with non–soy consumers in the United States (1, 2). However, after migration to the United States, immigrant risk approaches that seen in the West, suggesting that differences are not entirely genetic. Interestingly, the prevalence of primary or organ-confined prostate cancer may not account for this difference, because some studies suggest equal rates between Western and Eastern cultures (1), whereas more recent ones suggest that Chinese born in China seem to have rates of primary prostate cancer only 2-fold lower than those of American-born Chinese (12). Although there are clear limitations to epidemiologic studies that seek to associate individual dietary constituents with specific types of cancer, existing data are consistent with the notion that epigenetic factors, including dietary constituents, may modulate prostate cancer metastatic behavior and thus mortality.

We have done a series of mechanistic studies that support the notion that genistein may be acting to inhibit prostate cancer metastasis (13–15). Genistein was first shown to inhibit prostate cancer cell detachment, an initial and necessary step in the metastatic cascade (13). Effects were time and concentration dependent and involved physiologically relevant cellular mechanisms, necessary characteristics of a specifically acting drug. Specifically, genistein treatment caused focal adhesion kinase to form a molecular complex with ß1-integrin (13), a transmembrane adhesion protein important in regulating prostate cancer cell adhesion (15, 16), with later studies demonstrating that complex formation was an early event in focal adhesion complex formation (15). Focal adhesion kinase is a protein-tyrosine kinase that regulates cell adhesion and is up-regulated during prostate cancer progression (17). Since our initial report, others have described effects by genistein in a variety of model systems that directly support an antimetastatic mechanism, including decreased intestinal metastasis in rats (18), decreased invasion and lung metastasis of melanoma cells (19, 20), and decreased invasion with breast cancer (21) and glioblastoma cell lines (22). In a separate series of investigations, we showed that genistein would induce apoptosis in human prostate cancer cells (14), but went on to show that growth-inhibitory effects were only observed with supramicromolar concentrations (14, 17), thus calling into question the clinical relevance of growth inhibition. Although genistein activity, if operating in humans, would serve to antagonize metastasis, we only had anecdotal evidence of efficacy in the low nanomolar range (14). However, this was not thoroughly investigated, nor was its molecular mechanism understood.

In an effort to expedite genistein-based mechanistic studies, investigations were refocused on elucidating the mechanism by which human prostate cancer cells regulate adhesion and motility. By using microarrays to screen for genes differentially expressed during changes in prostate cancer cell adhesion, endoglin, a transforming growth factor ß (TGF-ß) transmembrane protein, was identified (23) and shown to regulate cell adhesion, migration, and invasion. TGF-ß is an important regulator of adhesion and motility in a variety of cell types, including prostate (24–26), We therefore went on to show that TGF-ß–mediated increases in prostate cell adhesion were dependent on p38 mitogen-activated protein kinase (MAPK; ref. 27), a member of the MAPK family of cell signaling proteins.

Cell adhesion and invasion are related but distinct cellular processes, with invasion being more closely linked to metastatic behavior. In this article, we show for the first time that p38 MAPK is necessary for TGF-ß–mediated increases in matrix metalloproteinase type 2 (MMP-2) activity and cell invasion. MMPs degrade extracellular matrix proteins and mediate cell invasion and metastatic behavior in a variety of cell types (for a review, see ref. 28). In human prostate, MMP-2 has been shown to be up-regulated during prostate cancer cell progression (29, 30). In the current study, we go on to show that genistein inhibits activation of p38 MAPK, MMP-2, and cell invasion. Importantly, efficacy is seen in the low nanomolar range, thus corresponding to blood concentrations associated with dietary consumption.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Materials. Genistein, phosphatase inhibitor mixture I and II, and gelatin (used in invasion assays) were all purchased from Sigma (St. Louis, MO). The p38 MAPK inhibitor, SB203580, and the structurally related inactive analog, SB202474, were from CalBiochem (San Diego, CA). Genistein, SB203580, and SB202474 were stored as stocks in DMSO, and were thawed just before use. Antibodies were obtained from the following sources: pan-specific TGF-ß neutralizing antibody, clone 1D11, R&D Systems (Minneapolis, MN); p38 MAPK, clone C-20, and ß-tubulin, clone D-10, Santa Cruz Biotechnology (Santa Cruz, CA); phospho-p38 MAPK (recognizes Thr180 and Tyr182), clone 9211S, Cell Signaling Technology (Beverly, MA); anti-mouse immunoglobulin horseradish peroxidase (HRP) and anti-rabbit immunoglobulin HRP, were part of the ECL Western blotting system (Amersham Pharmacia Biotech, Piscataway, NJ), and were used to detect proteins in Western blots. Recombinant human TGF-ß1 (R&D Systems) was resuspended and stored according to manufacturer's instructions and was used at a final concentration of 2 ng/mL, unless otherwise stated.

Constitutively active ß-galactosidase expression vector, pCMV-ßgal, was from Stratagene (La Jolla, CA). p38{alpha} subcloned into the pCDN vector (provided by Dr. Peter R. Young, SmithKline Beecham, King of Prussia, PA) was used to generate a p38AGF mutant (31). The mutant p38 was created by converting the TGY motif in p38 to AGF by site-directed mutagenesis, using a commercial kit (QuikChange, Stratagene). The resulting p38AGF mutant is identical to a previously described one (32).

Cell culture and transfection. The origin, characteristics, and culture conditions for PC3, PC3-M, and DU-145 established cell lines, as well as for human papilloma virus (HPV) transformed primary 1532NPTX (normal), 1532CPTX (cancer), 1542NPTX (normal), and 1542CP3TX (cancer) cell lines, have previously been described (17). All cells were maintained at 37°C in a humidified atmosphere of 5% carbon dioxide, with biweekly media changes. Cells were drawn from stored stock cells and replenished on a standardized periodic basis. All cells were routinely monitored for Mycoplasma. Cell viability was determined by counting the number of trypan blue–excluding cells under an inverted microscope, using a hemocytometer.

For transfection studies, cells were plated into 24-well plates the previous day and were then transfected using LipofectAMINE 2000 (Invitrogen, Carlsbad, CA) per manufacturer's instructions, using 600 ng of the indicated expression plasmid, along with 200 ng of pCMV-ßgal. After a 24-hour recovery period, cells were replated and 24 hours later treated as indicated. The use of a constitutively active ß-galactosidase vector allows identification of transfected cells in the context of a three-dimensional matrix used in invasion assays.

Zymography. Twenty-four hours after plating, cells were washed thrice with serum-free medium, placed into serum-free medium, treated as indicated, cultured for an additional 24 hours, and conditioned medium centrifuged at 3,000 rpm for 10 minutes to remove debris. In some studies, media were concentrated, thus allowing detection of both MMP-2 and MMP-9 (MMP-9 is present at much lower levels). Media were concentrated by placing in a Microcon YM-10 centrifugal filter (Millipore, Billerica, MA) and spinning at 14,000 x g for 30 minutes. For other studies, media were not concentrated, thus optimizing comparison of treatment-related effects on MMP-2. Conditioned media were separated by mixing with 2x sample dilution buffer [125 mmol/L Tris (pH 6.8), 1% SDS, 0.002% bromphenol blue, 10% glycerol], incubating 15 minutes at room temperature, and then separating on an 8% SDS polyacrlyamide gel containing 1 mg/mL gelatin under nonreducing conditions. Gels were then washed with 2.5% Triton X-100 in water for 30 minutes, rinsed for 15 minutes with 15 mmol/L Tris-HCl (pH 7.4), washed once in water, and incubated for up to 48 hours at 37°C in 20 mmol/L glycine (pH 8.3), 10 mmol/L CaCl2, and 1 µmol/L ZnCl2. Gels were then stained with 0.5% Coomassie Brilliant Blue G solution containing 10% acetic acid and 20% methanol for 30 minutes and destained with 10% acetic acid and 20% methanol. Areas of MMP activity were detected as clear bands against the blue-stained gelatin background. Dov 13 ovarian cancer cells express high levels of both MMP-9 and MMP-2, and their conditioned media served as a positive control. Cell viability was closely monitored for all experiments and treatment conditions described in this article, and was not adversely affected.

Cell invasion assays. Cell invasion assays were done as previously described, with modifications (23). Briefly, 24 hours after replating, cells were treated as indicated, detached by treatment with trypsin/EDTA, washed, resuspended in RPMI 1640 (Life Technologies, Inc., Grand Island, NY) with 0.1% bovine serum albumin, and 52 µL of cell suspension were placed into the upper chamber of a 48-well Boyden chamber unit (i.e., 1 x 104 cells per well). Cells were allowed to migrate for 9 to 15 hours through a Nuclepore Track-Etch Membrane (NC 983-1643; Whatman, Clifton, NJ), which contained 8-µm pores and was coated with 0.01% gelatin, toward serum-free NIH 3T3 conditioned medium present in the lower chamber. Cells were then fixed and stained according to manufacture's instructions, using Diff-Quick cell-staining kit (Dade Beharing AG; Dudingen, Switzerland). Membranes were then mounted onto slides, using Permount (Fisher Scientific, Hampton, NH). Using predetermined field coordinates, the number of invading and noninvading cells were then counted in each of five prospectively determined high-power fields (i.e., x100) for a given well, x4 wells for each treatment condition (i.e., n = 4). All statistical tests of invasion were two-sided, and changes were only considered statistically significant for P values ≤0.05.

In some instances, cells were transfected with expression vectors, along with a constitutively active ß-galactosidase expression vector, thus allowing detection of transfected cells. For these experiments, membranes were fixed with 2% formaldehyde and 0.2% glutaraldehyde in PBS for 10 minutes at room temp, as above, rinsed with PBS, and ß-galatosidase detected using a ß-galactosidase staining kit from Stratagene according to manufacturer's instructions. Cells were then stained as above with Diff-Quick, except that cells were only stained with solution 1 (i.e., xanthane dye). Use of dye solution 2 (thiazine dye) would have stained nuclei blue, thus interfering with the blue stain generated by ß-galactosidase.

Cell lysis and Western blot analysis. Cells were lysed and Western blots done as previously described (27), with modifications. Briefly, cells were lysed at 4°C in radioimmunoprecipitation lysis buffer [20 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 1 mmol/L EDTA, 0.5% Triton X-100, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L ß-glycerolphosphate] in the presence of protease inhibitors (1 µg/mL leupeptin, 1 µg/mL aprotinin, 1 mmol/L phenylmethylsulfonylfluoride, all from Sigma) and phosphatase inhibitors (10 mmol/L NaF, 1 mmol/L orthovanadate, phosphatase inhibitor mixture I and mixture II, both at 1:100 dilution; all from Sigma). The resultant clarified lysates, normalized for protein, were separated on a 10% SDS polyacrlyamide gel under reducing conditions and transferred onto 0.45-µm nitrocellulose (Schleicher & Schuell, Keene, NH) in a wet transfer cell. Blots were blocked with 20% bovine serum albumin (fraction V, Sigma) in TBST [10 mmol/L Tris-HCl (pH 7.6), 80 mmol/L NaCl, 0.1% Tween 20] for 1 hour at room temperature and probed overnight at 4°C with anti–phospho-p38 MAPK, diluted 1:1000 in TBST with 20% bovine serum albumin. After washing, membranes were incubated for 30 minutes at room temperature with anti-rabbit HRP–conjugated secondary antibody and visualized by chemiluminescence, using the ECL Western blotting kit (Amersham) per manufacturer's instructions. Membranes were then stripped by treating with stripping solution [100 mmol/L ß-mercaptoethanol, 2% SDS, 62.5 mmol/L Tris-HCl (pH 6.7)] at 50°C for 30 minutes and washing twice with TBST at room temperature. After blocking, membranes were reexposed (after readdition of HRP substrate) to ensure removal of antibody and then reprobed for total p38 MAPK, using antibody clone C-20 diluted 1:500, as well as for ß-tubulin, using antibody diluted 1:750.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Genistein decreases matrix metalloproteinase activity and inhibits cell invasion. MMPs are a family of enzymes whose function primarily relates to degradation of extracellular matrix proteins (28). Degradation of extracellular matrix is necessary for cell invasion, and changes in MMP activity are associated with metastatic behavior in a variety of cell types. In human prostate, increases in MMP-2 expression are seen in cancer, as compared with normal cells (29). If genistein were acting to inhibit cell invasion, then MMP-2 would be a likely target. The ability of genistein to inhibit MMP-2 activity was therefore tested in a panel of prostate cells lines recently characterized by us (17). Together, this panel contains members that span the spectrum of prostatic carcinogenesis, including HPV transformed primary cell lines as well as established metastatic cell lines. As can be seen in Fig. 1, after a treatment period of only 24 hours, genistein decreased MMP-2 activity in six of seven cell lines tested. More importantly, efficacy was observed in normal (1532NPTX and 1542NPTX), early cancer (1532CP1TX and 1542CP3TX), and established cancer (PC3 and PC3-M) cell lines. MMP-9 activity was low overall, with genistein decreasing activity in only two of four MMP-9–expressing cells. Similar findings were seen in replicate experiments done at a separate time.



View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. Genistein decreases MMP activity in human prostate. Twenty-four hours after plating, human prostate cells were changed to serum-free media, treated with the indicated concentrations of genistein (geni), and allowed to condition the media for 24 hours. Media were concentrated and MMP activity measured as described in Materials and Methods. For MMP-2, bands were quantitated, and percent change with genistein treatment, relative to the control for each cell line, depicted graphically. +C, positive control. Conditioned media from Dov 13 cells; high in MMP-2 and MMP-9.

 
The above findings show that the effect of genistein is not limited to a single cell line and that it has broad activity in human prostate. In-depth investigations were therefore undertaken to elucidate the mechanism by which human prostate cells regulate MMP-2 and invasion and to evaluate the effect of genistein on those regulatory pathways. PC3 and PC3-M cells were chosen for mechanistic studies because they have been extensively characterized by us and others, and we in particular have characterized their response to genistein and TGF-ß under a variety of experimental conditions (13–15, 17, 27, 33). In addition, early-stage prostate cell lines were all HPV transformed, raising concerns about their use in transfection experiments. Finally, relative to other cell lines, both PC3 and PC3-M exhibited relatively low levels of MMP-2 and seemed to be less sensitive to the effects of genistein. As such, they would provide a more rigorous test model.

TGF-ß is a physiologically important cytokine in human prostate cancer (27, 33–37), has previously been shown to increase MMP-2 activity in PC3 cells (38), and is produced by prostate cells, including PC3 and PC3-M cells (17). If genistein were in fact modulating MMP-2 activity in humans, then it should retain efficacy under conditions of physiologic MMP-2 activation. TGF-ß was first shown to induce MMP-2 in both PC3 and PC3-M cells (Fig. 2A). Next, the ability of genistein to inhibit TGF-ß–mediated induction of MMP-2 was shown by pretreating cells with different concentrations of genistein, then treating with TGF-ß and measuring the effects on MMP-2 activity (Fig. 2B). Genistein inhibited TGF-ß–mediated induction of MMP-2 in a concentration-dependent fashion in both cell lines tested. More importantly, efficacy was observed with genistein concentrations as low as 10 nmol/L in one of the cell lines tested (PC3), even after treatment for only 24 hours. This concentration corresponds to concentrations of free genistein attained in the blood after dietary consumption. Cell viability was monitored in the current experiment (and in all experiments) and was not affected by treatment with genistein, TGF-ß, chemical inhibitors of p38 MAPK (used below), or combinations of these agents under the associated experimental conditions (data not shown).



View larger version (51K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. Genistein inhibits TGF-ß–dependent activation of MMP-2. After changing to serum-free media, PC3 and PC3-M cells were treated (or not) with 2 ng/mL TGF-ß for 24 hours (A), or were pretreated with the indicated concentrations of genistein (geni) for 1 hour before adding TGF-ß, and then incubated for 24 hours (B). MMP activity was then measured in unconcentrated media. NP, no protein, loading buffer only (control lane).

 
If genistein-mediated inhibition of MMP-2 was functionally significant, then it should inhibit cell invasion. This was tested by treating cells with genistein for either 24 or 72 hours and measuring their ability to invade through gelatin toward conditioned media (Fig. 3). Genistein decreased invasion in a time- and concentration-dependent fashion in both cell lines tested. More importantly, after treatment for 72 hours, efficacy was observed with genistein concentrations as low as 10 nmol/L in both cell lines tested (two-sided p value <0.05). Thus, genistein will decrease prostate cell invasion at concentrations attained in the blood after dietary consumption.



View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. Genistein inhibits prostate cancer cell invasion. Twenty-four hours after plating, cells were treated with the indicated concentration of genistein for a total of either 24 or 72 hours, and cell invasion measured as described in Materials and Methods. Columns, mean from a single experiment run in replicates of four; bars, SE. Similar results were seen with multiple repeat experiments run at separate times. *, changes that differ significantly from nontreated control cells (two-sided t test). Green bar, range of concentrations of free genistein seen in the blood of soy consumers.

 
p38 mitogen-activated protein kinase regulates matrix metalloproteinase type 2 and cell invasion in human prostate. The above results show that TGF-ß up-regulates MMP-2 activity in human prostate, thus linking it to the regulation of cell invasion. Cell adhesion and invasion are closely linked cellular processes. We have recently shown that p38 MAPK is necessary for TGF-ß–mediated increases in cell adhesion in human prostate cells (27). We therefore investigated the possibility that p38 MAPK may also be important in regulating TGF-ß–dependent effects on MMP-2 and cell invasion in human prostate.

p38 MAPK is a serine/threonine kinase and is a member of the MAPK family of signaling proteins (for a review, see ref. 39). SB203580 is a specific inhibitor of p38 MAPK (40, 41). We have previously shown that SB203580 will block TGF-ß–mediated increases in cell adhesion (27). SB203580 was therefore used in the current study and was shown to inhibit cell invasion in both PC3 and PC3-M cells in a concentration-dependent fashion, relative to that of untreated control cells, as well as relative to that of cells treated with the inactive chemical homologue, SB203474 (Fig. 4A). Next, SB203580 was shown to block TGF-ß–mediated increases in MMP-2, relative to cells treated with inactive chemical homologue (Fig. 4B).



View larger version (51K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4. p38 MAPK regulates MMP-2 and cell invasion in human prostate. A, PC3 and PC3-M cells were treated for 24 hours with different concentrations of the p38 MAPK inhibitor, SB203580, or the inactive chemical analog, SB202474, and cell invasion measured. *, P < 0.05, values significantly below inactive chemical control (at corresponding concentrations); two-sided t test. Columns, mean of a single experiment (n = 4); bars, SE. Similar results seen with a replicate experiment, done at a different time (also n = 4). B, cells were pretreated (or not) for 1 hour with 10 µmol/L SB203580 or SB202474, before treatment with TGF-ß X 24 hours, and MMP-2 activity measured by zymography. C, cells were pretreated (or not) with SB203580 for 1 hour, and then with TGF-ß (or not) for an additional hour, and levels of phospho-p38 MAPK (pp38), total p38 MAPK, and ß-tubulin measured in equal amounts of cell protein by Western blot. Individual bands were quantitated, and the level of pp38 to ß-tubulin depicted graphically. With zymography and Western blot experiments, similar results were seen with multiple repeats done at separate times.

 
Although SB203580 is a specific inhibitor of p38 MAPK activity, it was important to evaluate the possibility that it may be acting as a nonspecific inhibitor of serine/threonine kinases and thereby preventing activation of p38 MAPK. Of particular concern were the transmembrane TGF-ß receptors (TGF-ßR). TGF-ß initially binds to the type II TGF-ß receptor (TGF-ßRII; a serine/threonine kinase), which then phosphorylates TGF-ßRI (a serine/threonine kinase), which in turn phosphorylates (i.e., activates) downstream members of the TGF-ß signaling cascade, including p38 MAPK (42–44). If SB203580 were nonspecifically inhibiting kinases upstream of p38 MAPK, then it would prevent phosphorylation of p38 MAPK. p38 MAPK is activated by phosphorylation on Thr180 and Tyr182, and this can be detected by Western blot using an activation-specific p38 MAPK antibody directed against both the Thr and Tyr phosphorylation sites. To evaluate whether SB203580 affected activation of p38 MAPK, cells were pretreated with SB203580 (or not), then treated with TGF-ß (or not), and p38 MAPK phosphorylation was evaluated by Western blot. As can be seen in Fig. 4C, TGF-ß–mediated phosphorylation of p38 MAPK was not inhibited by SB203580. This shows that SB203580 was not inhibiting regulatory elements upstream of p38 MAPK.

To confirm the role of p38 MAPK, its function in vivo was blocked by use of dominant-negative p38 MAPK, as previously described (27). The p38AGF mutant has point mutations at Thr180 and Tyr182, and thus it cannot be activated. For these experiments, prostate cells were first transfected with either wild-type (WT) or dominant-negative p38 MAPK constructs or vector control, and treated with TGF-ß (or not). Because TGF-ß treatment has been shown to increase levels of both total p38 MAPK (p38), as well as activated p38 MAPK (pp38, i.e., phospho-p38) in human prostate (27), the degree of p38 MAPK activation was determined by measuring pp38 and p38 protein levels by Western blot, and determining the ratio of pp38/p38 (Fig. 5A). As can be seen, total p38 MAPK protein levels were elevated in both WT and dominant-negative transfected cells, demonstrating increased expression. Whereas levels of activated p38 MAPK increased significantly in response to TGF-ß in vector control cells, baseline levels were much higher in WT transfectants, resulting in a lower proportional increase but overall much higher levels. In contrast, and more importantly, with dominant-negative cells, baseline levels of activated p38 MAPK were much lower, and treatment with TGF-ß caused little to no further increase.



View larger version (47K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5. Dominant-negative p38 MAPK inhibits cell invasion. A, PC3 and PC3-M cells were transfected with wild-type (WT), dominant-negative (DN) p38 MAPK, or vector only control (VC). Phospho-p38 MAPK (pp38) and total p38 MAPK (p38) protein levels were then measured by Western blot. Individual bands were quantitated, and the level of pp38 to p38 depicted in the graph. Equal protein loading was confirmed by staining the blot with Ponceau S. B, photomicrograph of cells cotransfected with WT p38 MAPK and constitutively active ß-gal vectors, which were allowed to invade through a gelatin-coated polycarbonate membrane that contained 8-µm pores. Transfected cells stain blue, nontransfected cells are pink, invading cells are in the focal plane, and noninvading cells are not in the focal plane. C, cells were transfected with either WT or dominant-negative p38 MAPK and treated with 2 ng/mL TGF-ß, 50 µmol/L genistein, 10 µmol/L SB203580, or SB202474 (or not) and cell invasion measured. *, P < 0.05, values significantly different from WT cells not treated with TGF-ß (two-sided t test). NS, values (indicated by arrows) that do not differ significantly. Invasion experiments were done in replicates of four. Columns, mean of a single experiment, with multiple replicates done at separate times yielding similar results; bars, SE. All other experiments were repeated at least once at a separate time, with similar results.

 
Next, the ability of dominant-negative p38 MAPK to inhibit cell invasion was evaluated. For these experiments, cells were cotransfected with constitutively active ß-gal, along with either WT or dominant-negative p38 MAPK. In this manner, invading and noninvading cells, transfected with dominant-negative or WT p38 MAPK, could be identified (Fig. 5B). TGF-ß increased cell invasion in p38 MAPK WT transfected cells (Fig. 5C). However, TGF-ß–mediated increases in cell invasion were completely abrogated in dominant-negative p38 MAPK transfected cells, thus demonstrating that p38 MAPK is necessary for TGF-ß–mediated increases in cell invasion. It can also be seen in Fig. 5C that SB203580, the chemical inhibitor of p38 MAPK, did not significantly decrease cell invasion compared with cells treated with inactive chemical control, SB202474, in cells transfected with dominant-negative p38 MAPK. This provides further evidence that SB203580 is not acting in a nonspecific fashion. Finally, in dominant-negative p38 MAPK transfected cells, genistein did not significantly decrease cell invasion, raising the notion that genistein may be inhibiting p38 MAPK related signaling.

Genistein blocks activation of p38 mitogen-activated protein kinase. A series of experiments was next conducted to investigate the relationship between genistein and p38 MAPK. First, both genistein and SB203580 were shown to inhibit cell invasion as well as TGF-ß–mediated increases in cell invasion (Fig. 6A). More importantly, when cells were treated with both genistein and SB203580, no further decrease in cell invasion was observed (Fig. 6B). This finding suggested that both genistein and SB203580 were acting on the same signaling pathway. Next, cells were pretreated with genistein (or not), then treated with TGF-ß (or not), and activation of p38 MAPK measured by Western blot (Fig. 6C). Treatment with TGF-ß alone increased phosphorylation of p38 MAPK. This effect was blocked when cells were preincubated with TGF-ß blocking antibody. More importantly, pretreatment of cells with genistein inhibited TGF-ß–mediated activation of p38 MAPK. Under the current assay conditions, inhibition was complete for PC3-M cells, and partial for PC3 cells.



View larger version (40K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 6. Genistein blocks TGF-ß–mediated activation of p38 MAPK. A and B, PC3 and PC3-M cells were treated with 2 ng/mL TGF-ß (3 ng/mL for PC3-M cells), 50 µmol/L genistein, 10 µmol/L SB203580 (p38 MAPK inhibitor), or 10 µmol/L SB202474 (inactive chemical control), or not, as indicated. A, cells were pretreated with TGF-ß for 1 hour, and effect in combination with either genistein or with p38 MAPK inhibition was evaluated. B, cells were pretreated with genistein for 1 hour, and effect in combination with p38 MAPK inhibition was evaluated. Cell invasion was then measured. Columns, mean percentage of invading cells, compared with untreated control cells (n = 4); bars, SE. *, P < 0.05, values that differ significantly from untreated control cells (two-sided t test). Similar results were seen in a separate experiment (also n = 4) done at a different time. C, cells were pretreated for 1 hour with genistein or with TGF-ß blocking antibody (5.0 µg/mL) followed by treatment with TGF-ß for an additional hour, as indicated. Levels of phospho-p38 MAPK (pp38), total MAPK (p38), and ß-tubulin were then measured by Western blot. Individual bands were quantitated and ratio of pp38 to ß-tubulin depicted graphically. Similar results were seen in multiple replicate experiments.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
MMPs are important regulators of cell invasion and are necessary for metastasis (28). MMP-2 in particular has been shown to be up-regulated during prostate cancer progression (29, 30). We show here for the first time that genistein is a broadly active inhibitor of MMP-2 activity in human prostate. Because cancer chemopreventive agents target processes associated with early phases of carcinogenesis (9), it was important that we showed efficacy in early transformed cells. Note that in addition to the seven cell lines evaluated for genistein-mediated decreases in MMP, we also attempted to evaluate LNCaP and normal prostate epithelial cells. However, these cells died upon serum withdrawal, precluding zymographic analysis. It was also important that we showed that genistein inhibited TGF-ß–mediated activation of MMP-2, and that activity was observed with low nanomolar concentrations of genistein. TGF-ß is a physiologically relevant activator of MMP-2 and is recognized as an important mediator of cell invasion (24–26, 38). Dietary consumption of genistein, in the form of soy, is associated with blood concentrations of free genistein, which range between 3 and 15 nmol/L (11). These concentrations directly overlap with lower limits of efficacy observed in the current study for genistein-mediated decreases in invasion.

Operation through physiologically relevant regulatory pathways is a basic property of effective drugs. Efficacy at clinically relevant concentrations is a basic property of any drug, and is of particular importance for cancer chemopreventive drugs (9, 45). With typical anticancer cytotoxic agents, escalation to clinical toxicity allows optimization of dose and efficacy. In contrast, chemopreventive agents are administered at nontoxic doses, and efficacy is only apparent after extended periods of administration (3). Taken together, the current study shows that genistein, given in dietary amounts, is capable of inhibiting MMP-2 and cell invasion. If operating in humans, this mechanism would explain, at least in part, epidemiologic findings that show reduced rates of prostate cancer metastasis and death in soy consumers (1, 2, 12, 46).

It is important to note, however, that epidemiologic studies provide associations between clinical outcome and behavior, in this case diet, which span a lifetime. There are significant limitations to extrapolating lifetime dietary exposure, or exposure during critical stages in development, to therapeutic efficacy in high-risk cohorts, for example, older American men at high risk for prostate cancer. In this regard, it is important to note that the current study, which focuses on invasion, as well as prior studies by us focusing on genistein-mediated effects on adhesion (13), both show increased efficacy with increased genistein concentration. This finding raises the notion that it may be possible to "make up" for a lack of lifetime dietary exposure by administration of higher amounts of genistein. This concept is currently being tested by us in a clinical trial wherein men with localized prostate cancer are treated with genistein in amounts that are twice those associated with dietary consumption. End points are biomarkers related to adhesion and invasion.

Although we could have chosen to focus invasion studies on any of a relatively wide array of extracellular matrix proteins or complex protein mixtures, we felt gelatin would be optimal. Because gelatin was used in zymogram assays, this would provide a direct comparison of activities. More importantly, gelatin is denatured collagen, and collagen represents a major extracellular matrix protein for human prostate (47).

To our knowledge, we show for the first time in any cell type that p38 MAPK is necessary for TGF-ß–mediated increases in MMP-2 activity as well as cell invasion. This represents an extension of our previous work in which we showed that p38 MAPK is necessary for TGF-ß–mediated increases in prostate cell adhesion (27). It is not clear if the primary effect of genistein is on p38 MAPK or on another enzyme that in turn regulates p38 MAPK activation. More importantly, however, we have previously shown that in an older cohort of men with prostate cancer, oral genistein will alter levels of protein-tyrosine phosphorylation in peripheral blood mononuclear cells (5). Thus, genistein alters cell signaling pathways in a clinical setting, directly supporting current findings.

We go on to show for the first time that genistein is blocking TGF-ß–mediated activation of p38 MAPK as well as dependent activation of MMP-2 and cell invasion. Concomitant phosphorylation on both threonine and tyrosine on p38 MAPK is associated with activation of its kinase activity (48). Because genistein has a tyrosine-like moiety, is known to inhibit protein-tyrosine kinase activity (49), and has been shown by us to alter protein-tyrosine phosphorylation in humans after p.o. dosing with dietary amounts of genistein (5), it is possible that genistein may be inhibiting the enzymes(s) directly upstream of p38 MAPK. Additional investigations will be required, however, before this can be determined.

Because MMPs are so important in regulating metastatic behavior, they are an obvious target for drug development. However, when tested clinically, MMP inhibitors have been disappointing (50). Lack of clinical activity is believed to stem from the fact that inhibitors used in the clinic directly targeted the active site of MMPs, which do not vary significantly among the over 20 different isoforms. Thus, it has not been possible to achieve specificity. Genistein works by targeting an upstream activator of MMP-2, thus avoiding problems with active site inhibitors. Given that genistein seemed to preferentially inhibit MMP-2, as compared with MMP-9, the current study supports the notion of specificity. However, additional studies will be required in order to more fully characterize genistein's spectrum of activity with respect to the different MMP isotypes.

In summary, we show for the first time that p38 MAPK is necessary for TGF-ß–mediated activation of MMP-2 and cell invasion, and that genistein inhibits p38 MAPK activation. We also show for the first time that genistein is a broadly active inhibitor of MMP-2 in human prostate cancer and that it will inhibit MMP-2 activation and invasion at the low nanomolar concentrations attained in the blood with dietary soy consumption. If genistein were exerting this activity in humans, it would support a causal relationship to epidemiologic findings. This possibility is being investigated in a phase 2 clinical study we are currently conducting in men with prostate cancer.


   Acknowledgments
 
Grant support: National Cancer Institute, NIH, Department of Health and Human Services grant CA099263 and Specialized Programs of Research Excellence grant CA90386 and the H Foundation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   Footnotes
 
Note: X. Huang and S. Chen contributed equally to this work.

Y. Liu is currently with the Department of Pathology, National Cancer Institute, NIH, Bethesda, Maryland. D. Deb is currently with the Ben May Institute of Cancer Research, University of Chicago, Chicago, Illinois.

Received 8/ 4/04. Revised 1/23/05. Accepted 2/10/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 1989;49:1857–60.[Abstract/Free Full Text]
  2. Shimizu H, Ross RK, Bernstein L, et al. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991;63:963–6.[Medline]
  3. Nabhan C, Bergan RC. Chemoprevention in prostate cancer. In: Bergan RC, editor. Cancer chemoprevention. Boston: Kluwer; 2001. p. 103–36.
  4. Clinical development plan: genistein. J Cell Biochem Suppl 1996;26:114–26.[Medline]
  5. Takimoto CH, Glover K, Huang X, et al. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1213–21.[Abstract/Free Full Text]
  6. Fischer L, Mahoney C, Jeffcoat AR, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer 2004;48:160–70.[CrossRef][Medline]
  7. Busby MG, Jeffcoat AR, Bloedon LT, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr 2002;75:126–36.[Abstract/Free Full Text]
  8. Bloedon LT, Jeffcoat AR, Lopaczynski W, et al. Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am J Clin Nutr 2002;76:1126–37.[Abstract/Free Full Text]
  9. Crowell JA, Holmes CJ. Agent identification and preclinical testing. In: Bergan RC, editor. Cancer chemoprevention. Boston: Kluwer; 2001. p. 1–30.
  10. Supko JG, Phillips LR. High-performance liquid chromatographic assay for genistein in biological fluids. J Chromatogr B Biomed Appl 1995;666:157–67.[CrossRef][Medline]
  11. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993;342:1209–10.[CrossRef][Medline]
  12. Cook LS, Goldoft M, Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol 1999;161:152–5.[CrossRef][Medline]
  13. Bergan R, Kyle E, Nguyen P, et al. Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to ß-1-integrin. Clin Exp Metastasis 1996;14:389–98.[CrossRef][Medline]
  14. Kyle E, Neckers L, Takimoto C, Curt G, Bergan R. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol Pharmacol 1997;51:193–200.[Abstract/Free Full Text]
  15. Liu YU, Kyle E, Lieberman R, et al. Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-b-1-integrin complex formation. Clin Exp Metastasis 2000;18:203–12.[CrossRef][Medline]
  16. Witkowski CM, Rabinovitz I, Nagle RB, Affinito KS, Cress AE. Characterization of integrin subunits, cellular adhesion and tumorigenicity of four human prostate cell lines. J Cancer Res Clin Oncol 1993;119:637–44.[CrossRef][Medline]
  17. Liu YQ, Kyle E, Patel S, et al. Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells. Prostate Cancer Prostatic Dis 2001;4:81–91.[CrossRef][Medline]
  18. Iishi H, Tatsuta M, Baba M, et al. Genistein attenuates peritoneal metastasis of azoxymethane-induced intestinal adenocarcinomas in Wistar rats. Int J Cancer 2000;86:416–20.[CrossRef][Medline]
  19. Yan C, Han R. Suppression of adhesion-induced protein tyrosine phosphorylation decreases invasive and metastatic potentials of B16-BL6 melanoma cells by protein tyrosine kinase inhibitor genistein. Invasion Metastasis 1997;17:189–98.[Medline]
  20. Yan C, Han R. Genistein suppresses adhesion-induced protein tyrosine phosphorylation and invasion of B16-BL6 melanoma cells. Cancer Lett 1998;129:117–24.[CrossRef][Medline]
  21. Shao ZM, Wu J, Shen ZZ, Barsky SH. Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines. Anticancer Res 1998;18:1435–9.[Medline]
  22. Penar PL, Khoshyomn S, Bhushan A, Tritton TR. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery 1997;40:141–51.[CrossRef][Medline]
  23. Liu Y, Jovanovic B, Pins M, Lee C, Bergan RC. Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene 2002;21:8272–81.[CrossRef][Medline]
  24. Loganadane LD, Vassy J, Legrand C, Fauvel-Lafeve F. Transforming growth factor-ß 1 increases the adhesion of MDA-MB-231 mammary adenocarcinoma cells to the microvascular subendothelium. Cell Adhes Commun 1999;7:57–71.[Medline]
  25. Festuccia C, Bologna M, Gravina GL, et al. Osteoblast conditioned media contain TGF-ß1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int J Cancer 1999;81:395–403.[CrossRef][Medline]
  26. Kostenuik PJ, Singh G, Orr FW. Transforming growth factor ß upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen. Clin Exp Metastasis 1997;15:41–52.[CrossRef][Medline]
  27. Hayes SA, Huang X, Kambhampati S, Platanias LC, Bergan RC. p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. Oncogene 2003;22:4841–50.[CrossRef][Medline]
  28. Stetler-Stevenson WG, Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 2001;11:143–52.[CrossRef][Medline]
  29. Upadhyay J, Shekarriz B, Nemeth JA, et al. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 1999;5:4105–10.[Abstract/Free Full Text]
  30. Wood M, Fudge K, Mohler JL, et al. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997;15:246–58.[CrossRef][Medline]
  31. McLaughlin MM, Kumar S, McDonnell PC, et al. Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase. J Biol Chem 1996;271:8488–92.[Abstract/Free Full Text]
  32. Derijard B, Raingeaud J, Barrett T, et al. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 1995;267:682–5.[Abstract/Free Full Text]
  33. Rohlff C, Blagosklonny MV, Kyle E, et al. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1. Prostate 1998;37:51–9.[CrossRef][Medline]
  34. Kim IY, Ahn HJ, Zelner DJ, et al. Genetic change in transforming growth factor ß (TGF-ß) receptor type I gene correlates with insensitivity to TGF-ß 1 in human prostate cancer cells. Cancer Res 1996;56:44–8.[Abstract/Free Full Text]
  35. Kim IY, Ahn HJ, Lang S, et al. Loss of expression of transforming growth factor-ß receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 1998;4:1625–30.[Abstract]
  36. Kim IY, Ahn HJ, Zelner DJ, et al. Loss of expression of transforming growth factor ß type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 1996;2:1255–61.[Abstract]
  37. Sehgal I, Baley PA, Thompson TC. Transforming growth factor ß1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 1996;56:3359–65.[Abstract/Free Full Text]
  38. Sehgal I, Thompson TC. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-ß1 in human prostate cancer cell lines. Mol Biol Cell 1999;10:407–16.[Abstract/Free Full Text]
  39. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003;101:4667–79.[Abstract/Free Full Text]
  40. Tong L, Pav S, White DM, et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat Struct Biol 1997;4:311–6.[CrossRef][Medline]
  41. Wilson KP, McCaffrey PG, Hsiao K, et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol 1997;4:423–31.[CrossRef][Medline]
  42. Heldin CH, Miyazono K, ten Dijke P. TGF-ß signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465–71.[CrossRef][Medline]
  43. Massague J. TGFß signaling: receptors, transducers, and Mad proteins. Cell 1996;85:947–50.[CrossRef][Medline]
  44. Chen F, Weinberg RA. Biochemical evidence for the autophosphorylation and transphosphorylation of transforming growth factor ß receptor kinases. Proc Natl Acad Sci U S A 1995;92:1565–9.[Abstract/Free Full Text]
  45. Takimoto CH. Basic pharmacokinetics and pharmacodynamic principals. In: Bergan RC, editor. Cancer Chemoprevention. Boston: Kluwer; 2001. p. 85–102.
  46. Adlercreutz H. Western diet and western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest 1990;50 Suppl 201:3–23.
  47. Pfohler C, Fixemer T, Jung V, et al. In situ hybridization analysis of genes coding collagen IV {alpha}1 chain, laminin ß1 chain, and S-laminin in prostate tissue and prostate cancer: increased basement membrane gene expression in high-grade and metastatic lesions. Prostate 1998;36:143–50.[CrossRef][Medline]
  48. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739–46.[CrossRef][Medline]
  49. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262:5592–5.[Abstract/Free Full Text]
  50. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657–72.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
B. Kumar, S. Koul, J. Petersen, L. Khandrika, J. S. Hwa, R. B. Meacham, S. Wilson, and H. K. Koul
p38 Mitogen-Activated Protein Kinase-Driven MAPKAPK2 Regulates Invasion of Bladder Cancer by Modulation of MMP-2 and MMP-9 Activity
Cancer Res., January 15, 2010; 70(2): 832 - 841.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L. Xu, Y. Ding, W. J. Catalona, X. J. Yang, W. F. Anderson, B. Jovanovic, K. Wellman, J. Killmer, X. Huang, K. A. Scheidt, et al.
MEK4 Function, Genistein Treatment, and Invasion of Human Prostate Cancer Cells
J Natl Cancer Inst, August 19, 2009; 101(16): 1141 - 1155.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Lakshman, L. Xu, V. Ananthanarayanan, J. Cooper, C. H. Takimoto, I. Helenowski, J. C. Pelling, and R. C. Bergan
Dietary Genistein Inhibits Metastasis of Human Prostate Cancer in Mice
Cancer Res., March 15, 2008; 68(6): 2024 - 2032.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C. S. Craft, L. Xu, D. Romero, C. P. H. Vary, and R. C. Bergan
Genistein Induces Phenotypic Reversion of Endoglin Deficiency in Human Prostate Cancer Cells
Mol. Pharmacol., January 1, 2008; 73(1): 235 - 242.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. Penza, C. Montani, A. Romani, P. Vignolini, P. Ciana, A. Maggi, B. Pampaloni, L. Caimi, and D. Di Lorenzo
Genistein Accumulates in Body Depots and Is Mobilized during Fasting, Reaching Estrogenic Levels in Serum that Counter the Hormonal Actions of Estradiol and Organochlorines
Toxicol. Sci., June 1, 2007; 97(2): 299 - 307.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
L. Nonn, D. Duong, and D. M. Peehl
Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells
Carcinogenesis, June 1, 2007; 28(6): 1188 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Matsuo, S. Amano, M. Furuya, K. Namiki, K. Sakurai, M. Nishiyama, T. Sudo, K. Tatsumi, T. Kuriyama, S. Kimura, et al.
Involvement of p38{alpha} Mitogen-activated Protein Kinase in Lung Metastasis of Tumor Cells
J. Biol. Chem., December 1, 2006; 281(48): 36767 - 36775.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Naguleswaran, M. Spicher, N. Vonlaufen, L. M. Ortega-Mora, P. Torgerson, B. Gottstein, and A. Hemphill
In Vitro Metacestodicidal Activities of Genistein and Other Isoflavones against Echinococcus multilocularis and Echinococcus granulosus
Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3770 - 3778.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
R. P Singh and R. Agarwal
Mechanisms of action of novel agents for prostate cancer chemoprevention.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
L. Xu and R. C. Bergan
Genistein Inhibits Matrix Metalloproteinase Type 2 Activation and Prostate Cancer Cell Invasion by Blocking the Transforming Growth Factor beta-Mediated Activation of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2-27-kDa Heat Shock Protein Pathway
Mol. Pharmacol., September 1, 2006; 70(3): 869 - 877.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Mimeault and S. K. Batra
Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies
Carcinogenesis, January 1, 2006; 27(1): 1 - 22.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, X.
Right arrow Articles by Bergan, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, X.
Right arrow Articles by Bergan, R. C.
Related Collections
Right arrow Preclinical Intervention
Right arrow Preclinical Intervention: In Vitro: Drugs, Mechanisms

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online